DK2718313T3 - Behandling af respiratoriske tilstande - Google Patents

Behandling af respiratoriske tilstande Download PDF

Info

Publication number
DK2718313T3
DK2718313T3 DK12727921.4T DK12727921T DK2718313T3 DK 2718313 T3 DK2718313 T3 DK 2718313T3 DK 12727921 T DK12727921 T DK 12727921T DK 2718313 T3 DK2718313 T3 DK 2718313T3
Authority
DK
Denmark
Prior art keywords
ccr2
cells
levels
chemokine
lys
Prior art date
Application number
DK12727921.4T
Other languages
English (en)
Inventor
Graham Cotton
Ola Winqvist
Original Assignee
Tla Targeted Immunotherapies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tla Targeted Immunotherapies Ab filed Critical Tla Targeted Immunotherapies Ab
Application granted granted Critical
Publication of DK2718313T3 publication Critical patent/DK2718313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3618—Magnetic separation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (5)

1. Bindingsreagens, der kan binde specifikt til kemokin-receptoren CCR2 til anvendelse ved behandling afen respiratorisk tilstand, hvor bindingsreagensen er immobiliseret på en fast bærer, der er indeholdt i en aferese-søjle, hvortil der påføres perifert blod fra en patient, således at kemokin-receptor CCR2-eksprimerende celler fjernes fra patientens perifre blod.
2. Bindingsreagens til anvendelse ifølge krav 1, hvor: (i) den respiratoriske tilstand er udvalgt blandt sarkoidose og kronisk obstruk-tiv lungesygdom (KOL); og/eller (ii) bindingsreagensen, der kan binde specifikt til CCR2, er en agonist eller en antagonist af CCR2; og/eller (iii) bindingsreagensen, der kan binde specifikt til CCR2, er udvalgt blandt et antistof og et kemokin, og hvor kemokinet er CCL2 (MCP-1), og/eller (iv) de CCR2-eksprimererende celler er monocytter eller eosinofiler eller lymfocytter, isærT-lymfocytter såsom centrale hukommelses-T-celler; og/eller (v) patienten er blevet udvalgt til behandling på basis af detektering af en stigning i niveauet af CCR2-eksprimerende celler, i niveauer af ekspression af CCR2 og/eller i niveauer af celler med høj ekspression af CCR2 i en prøve opnået fra patienten; og/eller (vi) 20-50 % af patientens blod påføres til søjlen i en enkelt behandling.
3. Fremgangsmåde til overvågning af behandling af en respiratorisk tilstand, omfattende at bestemme a) niveauerne af kemokin-receptor CCR2-eksprimerende celler b) niveauer af ekspression af CCR2; og/eller c) niveauer af celler med høj ekspression af CCR2 i en prøve af perifert blod opnået fra et individ, hvor: (i) høje niveauer af CCR2-eksprimerende celler, høje niveauer af ekspression af CCR2 eller høje niveauer af celler med høj ekspression af CCR2 eller forhøjede niveauer af CCR2-eksprimerende celler sammenlignet med en kontrol, forhøjede niveauer af ekspression af CCR2 sammenlignet med en kontrol eller forhøjede niveauer af celler med høj ekspression af CCR2 sammenlignet med en kontrol indikerer tilstedeværelse eller progression af den respiratoriske tilstand; (ii) formindskede niveauer af CCR2-eksprimerende celler og/eller formindskede niveauer af ekspression af CCR2 og/eller formindskede niveauer af celler med høj ekspression af CCR2 korrelerer med vellykket behandling, og hvor behandlingen er ifølge et af kravene 1 til 2.
4. Fremgangsmåde til at vælge en egnet behandling af en respiratorisk tilstand, omfattende at bestemme a) niveauerne af kemokin-receptor CCR2-eksprimerende celler b) niveauer af ekspression af CCR2; og/eller c) niveauer af celler med høj ekspression af CCR2 i en prøve opnået fra et individ, hvor høje niveauer af CCR2-eksprimerende celler, høje niveauer af ekspression af CCR2 eller høje niveauer af celler med høj ekspression af CCR2 eller forhøjede niveauer af CCR2-eksprimerende celler sammenlignet med en kontrol, forhøjede niveauer af ekspression af CCR2 sammenlignet med en kontrol eller forhøjede niveauer af celler med høj ekspression af CCR2 sammenlignet med en kontrol, resulterer i valg af en behandling som defineret i et hvilket som helst af kravene 1 til 2 til behandling af den respiratoriske tilstand.
5. Fremgangsmåde ifølge krav 4, hvor: (i) den respiratoriske tilstand er udvalgt blandt sarkoidose og kronisk obstruk-tiv lungesygdom (KOL); og/eller (ii) prøven er en prøve af perifert blod, eventuelt hvor cellerne er CCR2-eksprimerende monocytter eller lymfocytter, især T-lymfocytter såsom centrale hukommelses-T-celler.
DK12727921.4T 2011-06-13 2012-06-13 Behandling af respiratoriske tilstande DK2718313T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496377P 2011-06-13 2011-06-13
PCT/GB2012/051356 WO2012172346A2 (en) 2011-06-13 2012-06-13 Treating respiratory conditions

Publications (1)

Publication Number Publication Date
DK2718313T3 true DK2718313T3 (da) 2017-08-28

Family

ID=46317442

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12727921.4T DK2718313T3 (da) 2011-06-13 2012-06-13 Behandling af respiratoriske tilstande
DK17171064.3T DK3228631T3 (da) 2011-06-13 2012-06-13 Behandling af respiratoriske tilstande

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17171064.3T DK3228631T3 (da) 2011-06-13 2012-06-13 Behandling af respiratoriske tilstande

Country Status (4)

Country Link
EP (2) EP2718313B1 (da)
DK (2) DK2718313T3 (da)
ES (2) ES2637390T3 (da)
WO (1) WO2012172346A2 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (ja) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ビオチン化ケモカイン抗体複合体
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
WO2004026893A2 (en) * 2002-09-23 2004-04-01 Rmf Dictagene S.A. Synthetic chemokines labeled at selected positions
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
TW200800895A (en) * 2005-11-02 2008-01-01 Astrazeneca Ab Novel compounds
CN101443041A (zh) * 2006-05-12 2009-05-27 Ibd柱疗法国际股份公司 治疗炎性肠病的方法和装置
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ｃｃｒ２에 대한 항체
CA2736632C (en) * 2008-09-10 2018-07-31 Ith Immune Therapy Holdings Ab Treating inflammatory conditions

Also Published As

Publication number Publication date
EP3228631B1 (en) 2020-06-24
WO2012172346A3 (en) 2013-03-14
WO2012172346A2 (en) 2012-12-20
DK3228631T3 (da) 2020-09-28
EP3228631A2 (en) 2017-10-11
ES2637390T3 (es) 2017-10-13
ES2821375T3 (es) 2021-04-26
EP3228631A3 (en) 2018-01-10
EP2718313B1 (en) 2017-05-17
EP2718313A2 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
US10422800B2 (en) Treating respiratory conditions
EP3693041A1 (en) Treating cancer
EP2718723B1 (en) Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome
DK2718312T3 (da) Behandling af tilstande forbundet med sepsis
DK2718313T3 (da) Behandling af respiratoriske tilstande
WO2012172343A2 (en) Treating primary sclerosing cholangitis
WO2012172336A2 (en) Treating inflammatory skin diseases
WO2012172337A2 (en) Treating cardiovascular disease
EP2718310B1 (en) Treating mental disorders
EP2717940A1 (en) Treating conditions associated with metabolic syndrome
DK2718311T3 (da) Behandling af multipel sklerose
WO2012172339A2 (en) Treating inflammatory arthritis
WO2012172345A2 (en) Treating conditions associated with allergy